Showing results (1461-1470 of 1,955) with videos related to
Sort By:
Pageof 196
British Journal of Haematology|April 17, 2007
Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomasDeepti Behl, Kay Ristow, Svetomir N Markovic, et al.Journal of Thrombosis and Thrombolysis|August 6, 2005
The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481--the Home INR Study (THINRS)David B Matchar, Alan K Jacobson, Robert G Edson, et al.Journal of Personality Disorders|September 19, 2012
Socioeconomic-status and mental health in a personality disorder sample: the importance of neighborhood factorsZach Walsh, M Tracie Shea, Shirley Yen, et al.Cancer Medicine|February 8, 2023
Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipientsMarissa Z Powell, Kristin C Mara, Radhika Bansal, et al.Blood|July 27, 2001
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphomaL F Porrata, M A Gertz, D J Inwards, et al.Journal of Neuro-Oncology|January 31, 2021
Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFRKedar S Vaidya, Michael J Mitten, Adelyn L Zelaya-Lazo, et al.Gerontology & Geriatrics Education|November 18, 2011
Building psychosocial programming in geriatrics fellowships: a consortium modelRonald D Adelman, Pamela Ansell, Risa Breckman, et al.Integrative Cancer Therapies|November 21, 2009
Circadian clock manipulation for cancer prevention and control and the relief of cancer symptomsWilliam J M Hrushesky, James Grutsch, Patricia Wood, et al.British Journal of Haematology|April 7, 2009
Risk of non-Hodgkin lymphoma in association with germline variation in complement genesJames R Cerhan, Anne J Novak, Zachary S Fredericksen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2005
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphomaThomas E Witzig, Susan M Geyer, Irene Ghobrial, et al.Pageof 196